Accolade Partners has announced it has raised $235 million for its sixth fund, Accolade VI.
Accolade Partners, headquartered in Washington, D.C., and founded in 2000, is a venture capital and growth equity investment...more
OrbiMed has announced the closing of its next venture capital fund with $950 million in limited partner commitments.
OrbiMed, headquartered in New York City, is an investment firm dedicated to the healthcare sector, with...more
Metacrine, based in San Diego, Calif., is a biotechnology company focused on advancing research in nuclear hormone receptors for treatment of metabolic diseases originated at the Salk Institute for Biological Studies....more
The firm indicated the new fund will invest in advancements in science that may lead to therapeutic interventions in genetic diseases, cancer and orphan diseases, as well as back new technologies focused on the development of...more